Jim Cramer Labels Moderna A 'Big Disappointment,' But Suggests Doubling Down On Another Pharma Powerhouse
Bristol Myers Says New Data From Phase 3 DAYBREAK Trial Showed Decreased Rates Of Brain Volume Loss Were Sustained In Open-label Extension For Patients Treated With Zeposia (Ozanimod) For Relapsing Forms Of Multiple Sclerosis
Realty Income Analyst Ratings
Pfizer Unusual Options Activity
Wall Street's Most Accurate Analysts Weigh In On 3 Defensive Stocks With Over 7% Dividend Yields
Major breakthrough in cancer treatment? Pharmaceutical companies invest billions of dollars, competing to bet on targeted radiation therapy.
Radioactive drugs have the potential to become a significant breakthrough in cancer treatment. In the past year, global pharmaceutical giants such as bristol-myers squibb, astrazeneca, and eli lilly and co have invested approximately 10 billion US dollars to actively enter the field of radioactive drugs through acquisitions and collaborations, aiming to replicate the success of Novartis in the drugs Lutathera and Pluvicto. Currently, these radioactive drugs are mainly used to treat certain types of neuroendocrine tumors and prostate cancer, with the potential to expand to the treatment of more types of cancer in the future.
$1000 Invested In Crown Castle 20 Years Ago Would Be Worth This Much Today
Beyond The Numbers: 13 Analysts Discuss Pfizer Stock
ONEOK Raised to Overweight at Morgan Stanley, Expecting Upward Estimate Revisions
Best Real Estate Growth Stocks as the Sector Is Seeing a Revival
Social Security Payments Set For 2.5% Increase Next Year; Retirement-Oriented Dividend Stocks Like Coca-Cola, Wells Fargo See Gains
Cantor Fitzgerald Reiterates Overweight on Pfizer, Maintains $45 Price Target
Pfizer Analyst Ratings
'La Porte Pipeline Fire Near Spencer Highway Causes Road Closures, Evacuations' - Fox 26 Houston
VICI Props Analyst Ratings
Cantor Fitzgerald Reiterates Neutral on Bristol-Myers Squibb, Maintains $50 Price Target
Bristol-Myers Squibb Analyst Ratings
DeSantis Administration Cautions Against Pfizer, Moderna MRNA Covid Vaccines for Vulnerable Individuals, Cites Concerns Related To Rare Heart Conditions
Peering Into Dominion Energy's Recent Short Interest
What the Options Market Tells Us About AT&T